The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Clinical Care Guidelines for Cystic Fibrosis–Related Diabetes
Open accessAbstract
ystic fibrosis-related diabetes (CFRD) is the most common comorbidity in people with cystic fibrosis (CF), occurring in ϳ20% of adolescents and 40 -50% of adults (1).While it shares features of type 1 and type 2 diabetes, CFRD is a distinct clinical entity.It is primarily caused by insulin insufficiency, although fluctuating levels of insulin resistance related to acute and chronic illness also play a role.The additional diagnosis of CFRD has a negative impact on pulmonary function and survival in CF, and this risk disproportionately affects women (2-4).In contrast to patients with other types of diabetes, there are no documented cases of death from atherosclerotic vascular disease in patients with CFRD, despite the fact that some now live into their sixth and seventh decades.These guidelines are the result of a joint effort between the Cystic Fibrosis Foundation (CFF), the American Diabetes Association (ADA), and the Pediatric Endocrine Society (PES).They are intended for use by CF patients, their care partners, and health care professionals and include recommendations for screening, diagnosis, and medical management of CFRD.This report focuses on aspects of care unique to CFRD.A comprehensive summary of recommendations for all people with diabetes can be found in the ADA Standards of Medical Care, published annually in the January supplement to Diabetes Care (5).METHODS -In 2009, CFF in collaboration with ADA and PES convened a committee of CF and diabetes experts to update clinical care guidelines for CFRD.Investigators at Johns Hopkins University conducted evidence reviews on relevant clinical questions identified by the guidelines committee.The reviews were provided to the committee to use in developing recommendations.Where possible, the evidence for each recommendation was considered and graded by the committee using the ADA (5) and the U.S. Preventive Services Task Force (USP-STF) (6) grading systems (Table 1).Recommendations from existing published guidelines were used when available and appropriate, and these are indicated as consensus statements.The committee also made consensus recommendations for topics not included in the evidence reviews or for which limited evidence was available in the literature.Recommendations will be updated as warranted by new evidence, and the guidelines will be reviewed 3 years after release date to determine if an update is needed.A summary of the committee's recommendations is presented in Table 2.SCREENING -CFRD is often clinically silent.In other populations, the primary consequences of unrecognized diabetes are macrovascular and microvascular disease.In CF, the nutritional and pulmonary consequences of diabetes are of greater concern.CFRD is associated with weight loss, protein catabolism, lung function decline, and increased mortality (2,3,7-17), and thus regular screening is warranted. Screening tests for CFRDAlthough hemoglobin A1C (A1C) may become the standard screening test for type 2 diabetes (5), the committee concluded that it is not sufficiently sensitive for diagnosis of CFRD and thus should not be used as a screening test.Eight studies were identified that assessed A1C as a screening test in this population (7,18 -24).The authors of one prospective cohort study of 62 participants with CF and 107 healthy control subjects reported that A1C levels were higher in the CF group than among the control subjects, leading them to suggest that the use of A1C was appropriate (18).However, six studies (including two prospective cohort studies [7,21], two cross-sectional studies [19,20], one case-control study [23], and one case series [22[) with a total of 477 participants demonstrated low degrees of correlation between A1C and glucose tolerance status (7,19 -23).Additionally, a cross-sectional study of 191 participants
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes
Landon, M. B., Spong, C. Y., Thom, E., Carpenter, M. W., Ramin, S. M., Casey, B., Wapner, R. J., Varner, M. W., Rouse, D. J., Thorp, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902430 · Cited by 2,122
Clinical Practice Recommendations
Fowler, M. J. (2011) · Clinical Diabetes · doi:10.2337/diaclin.29.4.163 · Cited by 995
Stallings, V. A., Stark, L. J., Robinson, K. A., Feranchak, A. P., & Quinton, H. (2008) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2008.02.020 · Cited by 732
Self-citationCystic Fibrosis–Related Diabetes: Current Trends in Prevalence, Incidence, and Mortality
Moran, A., Dunitz, J., Nathan, B., Saeed, A., Holme, B., & Thomas, W. (2009) · Diabetes Care · doi:10.2337/dc09-0586 · Cited by 648
Self-citationConsensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis
Borowitz, D., Baker, R. D., & Stallings, V. (2002) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/j.1536-4801.2002.tb07816.x · Cited by 581
MILLA, C. E., WARWICK, W. J., & MORAN, A. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.3.9904075 · Cited by 367
Self-citationCystic Fibrosis Pulmonary Guidelines: Airway Clearance Therapies
Flume, P. A., Robinson, K. A., O'Sullivan, B. P., Finder, J. D., Vender, R. L., Willey-Courand, D.-B., White, T. B., & Marshall, B. C. (2009) · Respiratory Care · doi:10.4187/respcare.09540522 · Cited by 343
Self-citationEpidemiology of cystic fibrosis-related diabetes
Marshall, B. C., Butler, S. M., Stoddard, M., Moran, A. M., Liou, T. G., & Morgan, W. J. (2005) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.12.039 · Cited by 327
Self-citationDiagnosis, screening and management of cystic fibrosis related diabetes mellitus
Moran, A., Hardin, D., Rodman, D., Allen, H. F., Beall, R. J., Borowitz, D., Brunzell, C., Campbell III, P. W., Chesrown, S. E., Duchow, C., et al. (1999) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00058-3 · Cited by 293
Self-citation
Research works printed but not linked: 10
- Peraldo, 1998, Evaluation of glucose tolerance and insulin secretion in cystic fibrosis patients, Horm Res, 49, 65
- Hunkert, 1999, Potential impact of HbA1c determination on clinical decision making in patients with cystic fibrosis-related diabetes (Letter), Diabetes Care, 22, 1008, 10.2337/diacare.22.6.1008 · doi:10.2337/diacare.22.6.1008
- Goss, 2003, The effect of pregnancy on survival in women with cystic fibrosis, Chest, 124, 1460, 10.1378/chest.124.4.1460 · doi:10.1378/chest.124.4.1460
- Mekeel, 2007, Combined en bloc liver pancreas transplantation for children with CF, Liver Transpl, 13, 406, 10.1002/lt.21070 · doi:10.1002/lt.21070
- Madden, 1992, Intermediate-term results of heart-lung transplantation for cystic fibrosis, Lancet, 339, 1583, 10.1016/0140-6736(92)91842-V · doi:10.1016/0140-6736(92)91842-v
- Yung, 1998, Diabetic retinopathy in adult patients with cystic fibrosis-related diabetes, Respir Med, 92, 871, 10.1016/S0954-6111(98)90390-0 · doi:10.1016/s0954-6111(98)90390-0
- Hayes, 1994, Mangement dilemmas in the individual with cystic fibrosis and diabetes, J Am Diet Assoc, 94, 78, 10.1016/0002-8223(94)92046-X · doi:10.1016/0002-8223(94)92046-x
- Franzese, 2005, Can glargine reduce the number of lung infections in patients with cystic fibrosis-related diabetes?, Diabetes Care, 28, 2333, 10.2337/diacare.28.9.2333 · doi:10.2337/diacare.28.9.2333
- Brunzell, 2002, CFRD and abnormal glucose tolerance: overview and medical nutrition therapy, Diabetes Spectr, 15, 124, 10.2337/diaspect.15.2.124 · doi:10.2337/diaspect.15.2.124
- Sullivan, 1989, Diabetic microangiopathy in patients with cystic fibrosis, Pediatrics, 84, 642, 10.1542/peds.84.4.642 · doi:10.1542/peds.84.4.642
Cited by
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116
Metadata
- Authors
- Moran, A., Brunzell, C., Cohen, R. C., Katz, M., Marshall, B. C., Onady, G., Robinson, K. A., Sabadosa, K. A., Stecenko, A., Slovis, B., & the CFRD Guidelines Committee
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-12-01
- Volume
- 33
- Issue
- 12
- Pages
- 2697-2708
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2157745572
- Cited by
- 726
- References
- 62
- FWCI
- 20.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Care Guidelines for Cystic Fibrosis–Related Diabetes. https://app.cochat.ai/papers/10.2337/dc10-1768
- The paper
- Moran, A., Brunzell, C., Cohen, R. C., Katz, M., Marshall, B. C., Onady, G., Robinson, K. A., Sabadosa, K. A., Stecenko, A., Slovis, B., & the CFRD Guidelines Committee. (2010). Clinical Care Guidelines for Cystic Fibrosis–Related Diabetes. Diabetes Care. https://doi.org/10.2337/dc10-1768
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.